Free Newsletter
Daiichi sets up vaccine R&D; unit in Japan
Daiichi Sankyo has established a new Tokyo-based vaccine research unit at its existing Kasai R&D Center in Japan. The move follows the April announcement that Daiichi had set up another research unit inside the National Institute of Biomedical Innovation in Osaka, where the Japanese developer says it's already conducting exploratory vaccine research and searching for new adjuvants.
Researchers at the Tokyo unit will be hunting for new vaccines for infectious diseases, according to Daiichi's release. "Now, with two vaccine research units and partnerships with organizations inside and outside of the group, Daiichi Sankyo is poised to fully realize its dedication to producing new vaccines through continuing research efforts and to supplying safe and effective existing vaccines to the healthcare professionals and other persons in Japan who are waiting for them," the pharma company said in a statement.
- see this release from Daiichi
Related Article:
Daiichi shuffles R&D programs in global restructuring
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
SHARE
WITH: